Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Liver Disease

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44393   clinical trials with a EudraCT protocol, of which   7405   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    4,649 result(s) found for: Liver Disease. Displaying page 23 of 233.
    «« First « Previous 19  20  21  22  23  24  25  26  27  Next» Last»»
    EudraCT Number: 2017-004208-24 Sponsor Protocol Number: CLJC242A2201J Start Date*: 2018-08-14
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, double-blind, multicenter study to assess the safety, tolerability, and efficacy of a combination treatment of tropifexor (LJN452) and cenicriviroc (CVC) in adult patients with nonalc...
    Medical condition: Non-alcoholic Steatohepatitis (NASH)
    Disease: Version SOC Term Classification Code Term Level
    22.0 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) CZ (Completed) DE (Completed) BE (Completed) FR (Completed) PT (Completed) ES (Completed) LV (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-003107-29 Sponsor Protocol Number: N°005 Start Date*: 2015-08-07
    Sponsor Name:GALMED Pharmaceuticals LTD.
    Full Title: A Phase IIb, double blind, randomized controlled clinical trial to evaluate the efficacy and safety of two Aramchol doses versus placebo in patients with Non-Alcoholic- Steatohepatitis (NASH).
    Medical condition: Non-alcoholic Steatohepatitis in patients with two additional features of metabolic syndrome -overweight or obesity and Diabetes Mellitus type II or pre-diabetes.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) RO (Ongoing) LT (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-005558-21 Sponsor Protocol Number: LUM001-401 Start Date*: 2015-03-25
    Sponsor Name:Lumena Pharmaceuticals LLC
    Full Title: A Pilot, Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of LUM001, an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTi), in Patients with Primary Sclerosing Cholan...
    Medical condition: Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease of unknown aetiology. PSC is characterized by inflammation and fibrosis of the intra- and extrahepatic biliary tree re...
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004871 10036732 Primary sclerosing cholangitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-003048-63 Sponsor Protocol Number: MK-3655-001 Start Date*: 2020-12-21
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-3655 in Individuals With Pre-cirrhotic Nonalcoholic Steatohepatitis.
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    24.1 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) IT (Completed) SE (Prematurely Ended) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-002205-38 Sponsor Protocol Number: 747-207 Start Date*: 2015-12-02
    Sponsor Name:INTERCEPT PHARMACEUTICALS INC.
    Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled,Dose-Finding, Clinical Trial Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects with Primary Sclerosing Cholangitis
    Medical condition: Primary Sclerosing Cholangitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10019805 - Hepatobiliary disorders 10019805 Hepatobiliary disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-003925-42 Sponsor Protocol Number: ESR-19-14451 Start Date*: 2021-10-14
    Sponsor Name:Clinics of Munich University LMU
    Full Title: A randomized open-label phase II study on the effect of durvalumab and tremelimumab combined with personalized SIRT (p-SIRT), standard-dose SIRT (sd-SIRT) or immunotherapy followed by on-demand loc...
    Medical condition: Patients with hepatocellular cancer, not amenable to curative surgical or ablation treatment.
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036706 Primary liver cancer non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2004-002834-20 Sponsor Protocol Number: HCC-Rap-001 Start Date*: 2008-01-23
    Sponsor Name:Universitätsklinik für Innere Medizin IV, Klinische Abteilung Gastroenterologie und Hepatologie
    Full Title: Behandlung des fortgeschrittenen hepatozellulären Karzinoms mit dem mTOR-Inhibitor Rapamycin (HCC-Rap-001) Treatment of advanced hepatocellular carcinoma with the mTOR-inhibitor rapamycin (HCC-Ra...
    Medical condition: Advanced hepatocellular carcinoma (HCC)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2019-001957-16 Sponsor Protocol Number: BREAST-SK-001 Start Date*: 2019-10-31
    Sponsor Name:Národný onkologický ústav
    Full Title: Phase II study of Vinorelbine, cisplatin, disulfiram and copper in CTC_EMT positive refractory metastatic breast cancer.
    Medical condition: breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SK (Ongoing)
    Trial results: View results
    EudraCT Number: 2017-003710-58 Sponsor Protocol Number: 57238 Start Date*: 2018-07-17
    Sponsor Name:AZIENDA OSPEDALIERA UNIVERSITARIA POLICLINICO “PAOLO GIACCONE” DI PALERMO
    Full Title: Study to Investigate the Efficacy of elbasvir/grazoprevir Fixed-Dose Combination for 8 Weeks in G1b Treatment-Na¿ve, HCV-Infected Patients With non-severe Fibrosis, with or without glucose abnorm...
    Medical condition: chronic hepatitis C
    Disease: Version SOC Term Classification Code Term Level
    20.0 10019805 - Hepatobiliary disorders 10019805 Hepatobiliary disorders SOC
    20.0 10021881 - Infections and infestations 10021881 Infections and infestations SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-004040-70 Sponsor Protocol Number: BUC-56/PBC Start Date*: 2008-05-15
    Sponsor Name:Dr. Falk Pharma GmbH
    Full Title: Double-blind, randomised, placebo-controlled, multi-centre phase III clinical study comparing the combination of ursodeoxycholic acid capsules plus budesonide capsules to ursodeoxycholic acid capsu...
    Medical condition: PBC patients with an incomplete response to UDCA treatment defined by the failure to achieve s-AP levels < 1.5x upper limit of normal after at least 6 months of treatment with UDCA and with inflamm...
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004871 10036680 Primary biliary cirrhosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) FR (Completed) AT (Completed) NL (Completed) FI (Completed) ES (Completed) HU (Completed) GB (Completed) LT (Completed) DK (Completed) IT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2011-006132-24 Sponsor Protocol Number: CDEB025A2313 Start Date*: 2012-05-18
    Sponsor Name:Novartis Farmaceutica, S.A.
    Full Title: A multi-centre 3-year follow-up study to assess the viral activity in patients who failed to achieve sustained virologic response in Novartis-sponsored alisporivir studies for chronic hepatitis C p...
    Medical condition: Chronic hepatitis C patients who failed to achieve sustained virologic response (SVR24) on alisporivir or direct-acting antivirals (DAA) in previous Novartis-sponsored studies.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10021881 Infections and infestations SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) HU (Prematurely Ended) GB (Completed) PL (Prematurely Ended) IT (Prematurely Ended) DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-002325-38 Sponsor Protocol Number: A4250-008 Start Date*: Information not available in EudraCT
    Sponsor Name:Albireo AB
    Full Title: An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of A4250 in Children with Progressive Familial Intrahepatic Cholestasis Types 1 and 2 (PEDFIC 2)
    Medical condition: Progressive Familial Intrahepatic Cholestasis Types 1 and 2
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10076033 Progressive familial intrahepatic cholestasis PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) SE (Completed) GB (GB - no longer in EU/EEA) NL (Completed) BE (Completed) ES (Prematurely Ended) IT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2017-004316-18 Sponsor Protocol Number: 2006-05 Start Date*: 2017-11-21
    Sponsor Name:Jazz Pharmaceuticals
    Full Title: Defibrotide for Patients with Hepatic Veno-occlusive Disease (VOD): A Treatment IND Study
    Medical condition: Hepatic Veno-Occlusive Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004871 10047207 Veno-occlusive liver damage LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2009-017731-17 Sponsor Protocol Number: AIO-KRK-0109 Start Date*: 2011-02-01
    Sponsor Name:AIO-Studien-gGmbh
    Full Title: An open-label 2:1 randomized phase II study of panitumumab plus FOLFOXIRI or FOLFOXIRI alone as first-line treatment of patients with non-resectable metastatic colorectal cancer and RAS wild-type
    Medical condition: non-resectable metastatic colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10010036 Colorectal carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-020146-10 Sponsor Protocol Number: LEG-SIL-LTX-02 Start Date*: 2011-07-27
    Sponsor Name:ROTTAPHARM S.P.A.
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LEGALON SIL FOR THE TREATMENT OF HCV RECURRENCE IN STABLE LIVER TRANSPLANTED PATIENTS.
    Medical condition: HCV recurrence in stable liver transplanted patients not responding to treatment with peginterferon/ribavirin (i.e. the so called standard of care,SOC)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10008912 Chronic hepatitis C LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-001132-30 Sponsor Protocol Number: DIL-2011/04 Start Date*: 2011-06-07
    Sponsor Name:Všeobecná fakultní nemocnice v Praze
    Full Title: Non-invasive parameters in the evaluation of portal hypertension in patients with liver cirrhosis and their significance for the evolution of cardial complications.
    Medical condition: In the prevention of variceal bleeding betablockers are used. The efficacy of betablockers is evaluated by repeated HVPG measurement. The aims: To evaluate the relationship between the polymorphism...
    Disease: Version SOC Term Classification Code Term Level
    13.1 10019805 - Hepatobiliary disorders 10009210 Cirrhosis biliary LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2018-004258-77 Sponsor Protocol Number: CM-101-PSC-001 Start Date*: 2019-02-05
    Sponsor Name:ChemomAb Ltd.
    Full Title: A Phase 2, Open Label, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of CM-101 Administered for 12 Weeks in Adult Subjects with Primary Sclerosing Cholangitis.
    Medical condition: Treatment of Primary Sclerosing Cholangitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004871 10036732 Primary sclerosing cholangitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-005217-14 Sponsor Protocol Number: DCR-A1AT-202 Start Date*: 2022-03-09
    Sponsor Name:Dicerna Pharmaceuticals, Inc.
    Full Title: A Phase 2 Open-Label Extension Study to Evaluate the Safety and Pharmacodynamics of Belcesiran in Patients with PiZZ Alpha-1 Antitrypsin Deficiency Associated Liver Disease
    Medical condition: PiZZAlpha-1 Antitrypsin Deficiency Associated Liver Disease
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004850 10001806 Alpha-1 anti-trypsin deficiency LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-001698-25 Sponsor Protocol Number: LIVERHOPE_EFFICACY Start Date*: 2018-07-24
    Sponsor Name:IDIBAPS
    Full Title: Efficacy of the combination of simvastatin plus rifaximin in patients with decompensated cirrhosis to prevent ACLF development: a multicenter, double-blind, placebo controlled randomized clinical t...
    Medical condition: Patients with decompensated cirrhosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004871 10009209 Cirrhosis bilary LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) NL (Completed) FR (Completed) GB (GB - no longer in EU/EEA) DE (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-003108-15 Sponsor Protocol Number: UC-GIG-2003 Start Date*: 2022-11-04
    Sponsor Name:UNICANCER
    Full Title: A multicentric national phase II trial assessing TIslelizumab in monotherapy for patients with Hepatocellular Carcinoma Child-Pugh B and ALBI grade 1 or 2 liver function Score
    Medical condition: Hepatocellular Carcinoma (HCC), Child-Pugh B, ALBI grade 1 or 2 liver function
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073069 Hepatic cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 19  20  21  22  23  24  25  26  27  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Apr 06 06:51:22 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA